Skip to main content

Table 1 Pre-treatment variables for patients initially treated with 1 and 2 g of ceftriaxone included in the propensity score estimation before and after matching

From: 1g versus 2 g daily intravenous ceftriaxone in the treatment of community onset pneumonia – a propensity score analysis of data from a Japanese multicenter registry

Variables

Before matching

After matching

1 g

2 g

ASMD

1 g

2 g

ASMD

n = 290

n = 216

n = 175

n = 175

Median age (years)

81 [71–87]

78 [67–85]

0.043

79 [70–86]

77 [67–85]

0.054

Sex (Male)

167 (57.6)

146 (67.6)

0.208

117 (66.9)

112 (64.0)

0.060

Median body weight (kg)

50.0

[42.0–59.3]

53.4

[44.0–62.5]

0.176

52.0

[45.0–62.5]

52.6

[44.0–60.8]

0.088

Preexisting comorbidity

 Diabetes mellitus

77 (26.6)

44 (20.4)

0.146

39 (22.3)

38 (21.7)

0.014

 Malignancy

54 (18.6)

42 (19.4)

0.021

36 (20.6)

33 (18.9)

0.043

 Bronchial asthma

20 (6.9)

27 (12.5)

0.190

18 (10.3)

14 (8.0)

0.079

 COPD or bronchiectasis

46 (15.9)

69 (31.9)

0.384

44 (25.1)

45 (25.7)

0.013

 Cerebrovascular diseases

59 (20.3)

47 (21.8)

0.035

32 (18.3)

33 (18.9)

0.015

 Heart failure

46 (15.9)

47 (21.8)

0.151

32 (18.3)

32 (18.3)

< 0.001

 Liver disease

11 (3.8)

14 (6.5)

0.122

9 (5.1)

6 (3.4)

0.085

 Kidney disease

31 (10.7)

32 (14.8)

0.124

20 (11.4)

20 (11.4)

< 0.001

 Dementia

35 (12.1)

21 (9.7)

0.075

18 (10.3)

18 (10.3)

< 0.001

Prescribed drugs

 Prednisolone

8 (2.8)

13 (6.0)

0.160

8 (4.6)

8 (4.6)

< 0.001

 Anti-acid drug

81 (27.9)

79 (36.6)

0.186

55 (31.4)

53 (30.3)

0.025

 Sleeping drug

41 (14.4)

30 (13.9)

0.007

25 (14.3)

25 (14.3)

< 0.001

Community- acquired pneumonia

202 (69.7)

160 (74.1)

0.101

132 (75.4)

129 (73.7)

0.039

Risk factors for aspiration pneumonia

 Overt aspiration

35 (12.1)

11 (5.1)

0.251

10 (5.7)

10 (5.7)

< 0.001

 Vomiting

3 (1.0)

5 (2.3)

0.100

3 (1.7)

2 (1.1)

0.048

 Dysphagia

32 (11.0)

12 (5.6)

0.200

13 (7.4)

11 (6.3)

0.045

 Disturbance of consciousness

10 (3.4)

9 (4.2)

0.038

7 (4.0)

7 (4.0)

< 0.001

 Neuromuscular diseases

17 (5.9)

5 (2.3)

0.180

3 (1.7)

5 (2.9)

0.077

 Tube feeding

59 (20.3)

47 (21.8)

0.035

2 (1.1)

1 (0.6)

0.062

 Bedridden status

21 (7.2)

13 (6.0)

0.049

10 (5.7)

10 (5.7)

< 0.001

Vital signs upon arrival at hospital (median)

 RR (breaths/minute)

20 [18–24]

22 [20–26]

0.001

22 [18–26]

22 [18–26]

0.031

 SBP (mmHg)

131 [117–149]

131 [118–152]

0.061

133 [118–150]

130 [114–150]

0.043

 PR (beats/minute)

94 [84–107]

96 [83–110]

0.093

95 [84–109]

94 [83–110]

0.018

 BT (°C)

37.5 [36.8–38.3]

37.5 [36.7–38.1]

0.087

37.5 [36.8–38.1]

37.5 [36.7–38.1]

0.013

Laboratory data (median) and a chest xray finding at admission

 Hct (%)

37.0 [33.1–40.5]

36.9 [33.2–40.7]

0.023

37.1 [33.5–40.8]

36.9 [33.4–41.2]

0.026

 BUN (mg/dL)

18.0 [14–24]

17.9 [13.35–26]

0.025

17.0[13.4–25.0]

17.0[13.4–26.0]

0.056

 serum Na (mEq/L)

138 [135–140]

138 [136–140]

0.033

139 [135–140]

138 [135–140]

0.027

 Glu (mg/dL)

124 [106–153]

129 [109–154]

0.018

125 [109–157]

131 [110–159]

0.038

 Alb (mg/dL)

3.4 [3.1–3.8]

3.5 [3.2–3.9]

0.165

3.5 [3.1–3.9]

3.5 [3.1–3.9]

0.033

 Pleural effusion on chest xray

18 (6.2)

14 (6.5)

0.011

11 (6.3)

11 (6.3)

< 0.001

  1. Note: Data presented as No. (%) or median [interquartile range]. ASMDs absolute standardized mean differences; COPD chronic obstructive pulmonary disease; RR respiratory rate; SBP systolic blood pressure; PR pulse rate; BT body temperature; Hct hematocrit; BUN blood urea nitrogen; Na sodium; Glu glucose; Alb albumin